NEWS
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division.
PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment.
This collaboration leverages Pluri's 47,000 square foot GMP cell production facility and expertise in developing and manufacturing cell-based products.
The agreement supports Kadimastem's preparation for clinical trials and expansion into the U.S. market, particularly for an upcoming FDA Phase 2a study of AstroRx®.
This partnership highlights PluriCDMO™'s versatility and commitment to advancing innovative life-saving therapies
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1103Followers
69Following
7648Visitors
Follow